An independent data monitoring committee assessed that the PRECISION1 trial of nab-sirolimus in solid tumors would not meet ...

64Cu-SAR-bisPSMA is a novel PET imaging agent for PSMA-positive prostate cancer. The designation allows Clarity ...

In an interview with Peers & Perspectives in Oncology, Thomas “Greg” Knight, MD, discusses how Levine Cancer set up its ...

Nazli Dizman, MD, discusses the current accountability measures for enforcing the language of respect guidelines in renal cell carcinoma.

Ira Zackon, MD, discusses what strategies community oncology practices can implement to address racial and socioeconomic disparities in chronic lymphocytic leukemia.

IAN KROP, MD, PHD: For those of you who are selecting first-line regimens, what chemotherapy do you use? Do you use ...

The FDA issued a complete response letter for linvoseltamab aimed at treating relapsed/refractory multiple myeloma post ...

Biagio Ricciuti, MD, discussed findings from a retrospective study exploring the use of immune checkpoint inhibitors for ...

The VISTA-101 clinical trial is investigating KVA12123, a VISTA-blocking immunotherapy, in advanced solid tumors.

Jeff Sharman, MD, discusses the background of the ELEVATE-TN trial and its long-term efficacy data.

During a Case-Based Roundtable® event, Laahn Foster, MD, discussed a patient case and outcomes of the COMMANDS trial of ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...